Samaritan Hopes to Expedite Time-to-Market With FDA-Preferred, Reviewer- Friendly, Electronic Regulatory Submission of Positive HIV Phase II Data

Samaritan Hopes to Expedite Time-to-Market With FDA-Preferred, Reviewer- Friendly, Electronic Regulatory Submission of Positive HIV Phase II Data

		SAMARITAN PHARMACEUTICALS CORPORATE LOGO Samaritan Pharmaceuticals, in collaboration with Georgetown University, develops and strives to commercialize scientific breakthrough innovations for: Alzheimer's (AD) Drugs, to inhibit glucocorticoid-mediated neurotoxicity, an Animal Model to test AD drugs, an AD Diagnostic; a Breast Cancer Diagnostic; a peptide to bind Cholesterol and a late stage Phase II statistically significant HIV drug. Samaritan's patented pipeline is built on a, cholesterol-metabolism and glucocorticoid-biosynthesis, technology platform which is scientifically considered to be a successful therapeutic approach. (PRNewsFoto)[AS] LAS VEGAS, NV USA

LAS VEGAS, April 3 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals Inc. (OTC Bulletin Board: SPHC) announced today that it has obtained the services of Octagon Research Solutions, a regulatory consulting service specializing in electronic regulatory submissions, clinical information management, technical writing and dossier preparation. Samaritan hopes to expedite its HIV drug time-to-market by using FDA preferred fully electronic submissions which are FDA reviewer friendly. E-Submissions are increasingly becoming a key component of the regulatory approval process and save both money and precious time to regulatory approval. Eugene Boyle, CFO of Samaritan Pharmaceuticals, stated, "We take pride in our HIV Phase II positive data and Octagon is helping us to reflect that pride. In the future, we plan to use electronic tools to enhance the ever important, quality and timeliness, of data gathered during clinical trials, and the speed by which the data is gathered, for the entire regulatory life cycle of a drug." (Photo: http://www.newscom.com/cgi-bin/prnh/20030129/SPHCLOGO ) About Samaritan Pharmaceuticals Samaritan Pharmaceuticals, in collaboration with Georgetown University, strives to commercialize breakthrough scientific innovation. Samaritan is primarily focused on the development of innovative therapies for Alzheimer's, Cancer, Cholesterol Reduction and HIV. The science, that separates Samaritan's patented pipeline, closest to commercialization includes: a completed HIV Phase II trial with positive significant data; an Animal (rat) model used to test Alzheimer's drugs; an Alzheimer's (Predictor) Diagnostic and Breast Cancer (Tumor Aggressiveness) Diagnostic; a Peptide that binds cholesterol; and a series of innovative neuroprotective compounds. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 26, 2002. The company undertakes no duty to update forward-looking statements. Contact: Samaritan Pharmaceuticals, Inc., 702/735-7001, Fax 702/737-7016 Gene Boyle, Business Development, Email GeneBoyle@aol.com Doug Bessert, Investor Relations, Email DougBessert@aol.com To receive future press releases and newsletters automatically, or for more information, visit our Web site at http://www.samaritanpharmaceuticals.com .